ARTICLE | Deals
Biogen strengthens push into nephrology with $5.6B Apellis deal
Adding pair of growth drivers, commercial infrastructure as kidney program acquired with HI-Bio moves through Phase III testing
April 1, 2026 12:16 AM UTC
Biogen’s acquisition of Apellis for $5.6 billion up front adds a pair of growth drivers while providing the biotech with commercial infrastructure in nephrology to complement its 2024 acquisition of HI-Bio.
Assuming its completion, the agreement will add Empaveli and Syfovre, two formulations of pegcetacoplan, to the marketed drug portfolio of Biogen Inc. (NASDAQ:BIIB). They brought in a combined $689.4 million across immune-mediated renal and ophthalmic indications in 2025...